Company news

Regeneron Pharmaceuticals, Inc. news in 2022

Regeneron Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer

December 22, 2022

Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

December 18, 2022

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis

December 15, 2022

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis

December 14, 2022

Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types

November 30, 2022

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

November 16, 2022

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

November 10, 2022

Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)

November 7, 2022

Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders

November 2, 2022

Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection

October 20, 2022

EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review

October 11, 2022

Regeneron Elects Dr. Craig B. Thompson to Board of Directors

October 2, 2022

Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

September 27, 2022

Regeneron Announces Investor Call and Webcast at ESMO 2022

September 8, 2022

Regeneron Reports Second Quarter 2022 Financial and Operating Results

August 2, 2022

Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation

July 25, 2022

Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis

July 13, 2022

Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022

July 5, 2022

Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)

June 30, 2022

FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

June 6, 2022

Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer

June 1, 2022

Regeneron Completes Acquisition of Checkmate Pharmaceuticals

May 30, 2022

FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

May 19, 2022

Regeneron Reports First Quarter 2022 Financial and Operating Results

May 3, 2022

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

April 18, 2022

Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

April 6, 2022

Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022

April 4, 2022

FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

April 3, 2022

Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting

February 10, 2022

FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

February 9, 2022

Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

February 3, 2022

Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer

January 27, 2022

Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis

January 18, 2022

Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on

January 12, 2022

Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States

January 6, 2022

Calls in 2022

Decks in 2022